At the dawn of the transcriptomic medicine. Issue 3 (February 2021)

• Record Type: Journal Article
• Authors: Koks, Gea; Pfaff, Abigail L; Bubb, Vivien J; Quinn, John P; Koks, Sulev
• Is Part Of: Experimental biology and medicine. Volume 246:Issue 3(2021)
• Page Start: 286
• Page End: 292
• Publication Date: 2021-02
• Subjects: Transcriptome -- RNA-Seq -- gene expression profiling -- precision medicine -- genomics -- molecular targeted therapy; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/1535370220954788
• Languages: English
• ISSNs: 1535-3702

Abstract

Progress in genomic analytical technologies has improved our possibilities to obtain information regarding DNA, RNA, and their dynamic changes that occur over time or in response to specific challenges. This information describes the blueprint for cells, tissues, and organisms and has fundamental importance for all living organisms. This review focuses on the technological challenges to analyze the transcriptome and what is the impact of transcriptomics on precision medicine. The transcriptome is a term that covers all RNA present in cells and a substantial part of it will never be translated into protein but is nevertheless functional in determining cell phenotype. Recent developments in transcriptomics have challenged the fundamentals of the central dogma of biology by providing evidence of pervasive transcription of the genome. Such massive transcriptional activity is challenging the definition of a gene and especially the term "pseudogene" that has now been demonstrated in many examples to be both transcribed and translated. We also review the common sources of biomaterials for transcriptomics and justify the suitability of whole blood RNA as the current optimal analyte for clinical transcriptomics. At the end of the review, a brief overview of the clinical implications of transcriptomics in clinical trial design and clinical diagnosis is given. Finally, we introduce the transcriptome as a target for modern drug development as a tool for extending our capacity for precision medicine in multiple diseases.